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in the competence of GPs and hospital doctors to
perform a range of elective minor surgical procedures,
in terms of the safety, quality and cost of care.
Design: A prospective randomised controlled
equivalence trial was undertaken in consenting patients
presenting at general practices and needing minor
surgery.
Setting: The study was conducted in the south of
England. 
Participants: Consenting patients presenting at
general practices who needed minor surgery in
specified categories for whom the recruiting doctor felt
able to offer treatment or to be able to refer to a
colleague in primary care.
Interventions: On presentation to their GP , patients
were randomised to either treatment within primary
care or treatment at their local hospital. Evaluation was
by assessment of clinical quality and safety of outcome,
supplemented by examination of patient satisfaction
and cost-effectiveness. 
Main outcome measures: Two independent observers
assessed surgical quality by blinded assessment of wound
appearance, between 6 and 8 weeks postsurgery, from
photographs of wounds. Other measures included
satisfaction with care, safety of surgery in terms of
recognition of and appropriate treatment of skin
malignancies, and resource use and implications. 
Results: The 568 patients recruited (284 primary care,
284 hospital) were randomised by 82 GPs. In total, 637
skin procedures plus 17 ingrowing toenail procedures
were performed (313 primary care, 341 hospital) by 65
GPs and 60 hospital doctors. Surgical quality was
assessed for 273 (87%) primary care and 316 (93%)
hospital lesions. Mean visual analogue scale score in
hospital was significantly higher than that in primary
care [mean difference = 5.46 on 100-point scale; 95%
confidence interval (CI) 0.925 to 9.99], but the clinical
importance of the difference was uncertain. Hospital
doctors were better at achieving complete excision of
malignancies, with a difference that approached
statistical significance [7/16 GP (44%) versus 15/20
hospital (75%), 2 = 3.65, p = 0.056]. The proportion
of patients with post-operative complications was
similar in both groups. The mean cost for hospital-
based minor surgery was £1222.24 and for primary
care £449.74. Using postoperative complications as an
outcome, both effectiveness and costs of the
alternative interventions are uncertain. Using
completeness of excision of malignancy as an outcome,
hospital minor surgery becomes more cost-effective.
The 705 skin procedures undertaken in this trial
generated 491 lesions with a traceable histology report:
36 lesions (7%) from 33 individuals were malignant or
premalignant. Chance-corrected agreement (kappa)
between GP diagnosis of malignancy and histology was
0.45 (95% CI 0.36 to 0.54) for lesions and 0.41 (95%
CI 0.32 to 0.51) for individuals affected by malignancy.
Sensitivity of GPs for detection of malignant lesions was
66.7% (95% CI 50.3 to 79.8) for lesions and 63.6%
(95% CI 46.7 to 77.8) for individuals affected by
malignancy. 
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Abstract
A prospective randomised comparison of minor surgery in
primary and secondary care. The MiSTIC trial
S George,1* P Pockney,2 J Primrose,2 H Smith,3 P Little,4 H Kinley,2 R Kneebone,5
A Lowy,6 B Leppard,7 N Jayatilleke1 and C McCabe8
1 Public Health Sciences and Medical Statistics, University of Southampton School of Medicine, UK
2 University Surgery, University of Southampton School of Medicine, UK
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* Corresponding authorConclusions: The quality of minor surgery carried out
in general practice is not as high as that carried out in
hospital, using surgical quality as the primary outcome,
although the difference is not large. Patients are more
satisfied if their procedure is performed in primary
care, largely because of convenience. However, there
are clear deficiencies in GPs’ ability to recognise
malignant lesions, and there may be differences in
completeness of excision when compared with hospital
doctors. The safety of patients is of paramount
importance and this study does not demonstrate that
minor surgery carried out in primary care is safe as it is
currently practised. There are several alternative
models of minor surgery provision worthy of
consideration, including ones based in primary care that
require all excised tissue to be sent for histological
examination, or that require further training of GPs to
undertake the necessary work. The results of this study
suggest that a hospital-based service is more cost-
effective. It must be concluded that it is unsafe to leave
minor surgery in the hands of doctors who have never
been trained to do it. Further work is required to
determine GPs’ management of a range of skin
conditions (including potentially life-threatening
malignancies), rather than just their recognition of them.
Further economic modelling work is required to look at
the potential costs of training sufficient numbers of GPs
and GPs with special interests to meet the demand for
minor surgery safely in primary care, and of the
alternative of transferring minor surgery large-scale to
the hospital sector. Different models of provision need
thorough testing before widespread introduction.
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Objectives
The objective of this study was to determine
whether there is equivalence in the competence of
GPs and hospital doctors to perform a range of
elective minor surgical procedures, in terms of the
safety, quality and cost of care.
The aims were:
● to conduct a randomised controlled equivalence
trial of minor surgery in two settings 
● to collect data on quality of surgery, patient
satisfaction, patient safety and cost of procedure
in two settings
● to review data from this trial and from other
sources in order to consider future direction
and future research in this area.
Methods
Design
This prospective randomised controlled
equivalence trial was undertaken in consenting
patients presenting at general practices and
needing minor surgery.
Setting
The study was conducted in the south of England.
At the time of this trial, minor surgery provision
was provided mainly via a fee for service contract
with general medical practitioners, with some
serious pathology treated in hospital.
Participants
Participants were consenting patients presenting 
at general practices. They all needed minor
surgery in specified categories and the 
recruiting doctor felt able to offer treatment 
or to be able to refer to a colleague in primary
care.
Interventions
Patients were randomised, on presentation to their
GP, to either treatment within primary care or
treatment at their local hospital. Evaluation was by
assessment of clinical quality and safety of
outcome, supplemented by examination of patient
satisfaction and cost-effectiveness. 
Main outcome measures
The primary measure was surgical quality assessed
by blinded assessment of wound appearance,
between 6 and 8 weeks postsurgery, by two
independent observers, using photographs of
wounds. Secondary measures included satisfaction
with care, which was obtained by means of a
patient questionnaire; safety of surgery in terms of
recognition of and appropriate treatment of skin
malignancies, obtained by an examination of
histological material supplied and cross-
referencing with referral forms from GPs; and
resource use and implications. 
Results
In total, 568 patients were recruited (284 primary
care, 284 hospital) and randomised by 82 GPs.
Altogether, 637 skin procedures plus 17 ingrowing
toenail procedures were performed (313 primary
care, 341 hospital) by 65 GPs and 60 hospital
doctors. Surgical quality was assessed for 273
(87%) primary care and 316 (93%) hospital
lesions. Mean visual analogue scale score in
hospital was significantly higher than that in
primary care [mean difference = 5.46 on 
100-point scale; 95% confidence interval (CI)
0.925 to 9.99], but the clinical importance of the
difference was uncertain. Patients tended to be
more satisfied with procedures in primary care
and to report less inconvenience from their
procedure. Hospital doctors were better at
achieving complete excision of malignancies, with
a difference that approached statistical significance
[7/16 GP (44%) versus 15/20 hospital (75%), 
2 = 3.65, p = 0.056]. The proportion of patients
with post-operative complications was similar in
both groups. The mean cost for hospital-based
minor surgery was £1222.24 and for primary care
£449.74. Using postoperative complications as an
outcome, both effectiveness and costs of the
alternative interventions are uncertain. Using
completeness of excision of malignancy as an
outcome, hospital minor surgery becomes more
cost-effective.
The 705 skin procedures undertaken in this trial
generated 491 lesions with a traceable histology
report: 36 lesions (7%) from 33 individuals were
Executive summaryx
malignant or premalignant. Chance-corrected
agreement (kappa) between GP diagnosis of
malignancy and histology was 0.45 (95% CI 0.36
to 0.54) for lesions and 0.41 (95% CI 0.32 to 0.51)
for individuals affected by malignancy. Sensitivity
of GPs for detection of malignant lesions was
66.7% (95% CI 50.3 to 79.8) for lesions and 63.6%
(95% CI 46.7 to 77.8) for individuals affected by
malignancy. 
Conclusions
The quality of minor surgery carried out in
general practice is not as high as that carried out
in hospital, using surgical quality as the primary
outcome, although the difference is not large.
Patients are more satisfied if their procedure is
performed in primary care, however, largely
because of advantages in terms of convenience.
However, there are clear deficiencies in the ability
of GPs to recognise malignant lesions, and there
may be differences in completeness of excision
when compared with hospital doctors. 
The safety of patients is of paramount importance
and this study does not demonstrate that minor
surgery carried out in primary care is safe as it is
currently practised. There are several alternative
models of minor surgery provision worthy of
consideration, including ones based in primary
care that require all excised tissue to be sent for
histological examination, or that require further
training of GPs to undertake the necessary work.
The results of this study suggest that a hospital-
based service is more cost-effective, but at the
moment there is not the capacity in hospitals to
take on the workload of minor surgery, and it
would likely be unpopular with patients if it were
to happen. It must be concluded that it is unsafe
to leave minor surgery in the hands of doctors
who have never been trained to do it. If the
capacity to undertake the work is present in
primary care, then the increased costs associated
with training doctors to do it must be borne. 
Suggestions for further research
Further work is required to determine GPs’
management of a range of skin conditions
(including potentially life-threatening
malignancies), rather than just their recognition 
of them. Further economic modelling work is
required to look at the potential costs of training
sufficient numbers of GPs and GPs with special
interests to meet the demand for minor surgery
safely in primary care, and of the alternative of
transferring minor surgery large-scale to the
hospital sector. Different models of provision 
need thorough testing before widespread
introduction.
Executive summaryBackground
Minor surgery has formed part of general practice
(family practice) throughout its history. Indeed, in
the UK, GPs’ clinics and facilities are normally
referred to as their ‘surgeries’. However, the range
of procedures performed, the facilities and
resources available, the training structures and
requirements of the practising doctor, and the
contractual arrangements that pertain to the
doctor vary widely between and within different
healthcare systems around the developed world.
This study concentrates on the situation in the
UK, except where the literature suggests issues
that may be as relevant in their country of origin
as here.
Historical context
Minor surgery offered by GPs within the NHS
declined during the period from 1948, the date of
inception of the NHS, to the mid-1980s.1 This
decline was ascribed to two main causes: first, the
limiting contractual arrangements based on a
capitation system that existed between
independent GPs and commissioning health
authorities; and, second, the perceived wish of
patients to be treated by specialists. There was no
financial incentive for GPs to undertake minor
surgery, most patients were referred to secondary
care (hospitals) for procedures that were provided
there free of charge to the patient, and
consequently the range and number of surgical
procedures performed in general practice
declined sharply. A few enthusiasts maintained the
tradition, funded by ad hoc arrangements with
their local health authorities.2–4
The 1990 contract for GPs in England and Wales
specified an item-of-service payment for minor
surgical procedures, which replaced an element of
per capita funding and contributed to target
income.5 The money that was directed at this
initiative did not increase the total that GPs could
earn, therefore, but it introduced a new incentive
to perform minor surgery that reflected the
prevailing political agenda of the times. The
stated aim of the reforms was, in part, to try to
transfer some procedures that were being
performed in secondary care to primary care. This
reflected the needs of the government to reduce
the political pressure that long waiting lists for
hospital services were generating. It was also a
reaction to several publications advocating
primary care surgery as being more cost-effective,
equal in quality to hospital care, and better
received by patients than hospital care for some
procedures. The widely held belief was that most
GPs had acquired sufficient skills in minor surgical
techniques during their hospital-based
prequalification and postqualification training to
allow them to perform a variety of procedures
safely, conveniently and cost-effectively for
patients.2,6,7
The contract specified that in order to be able to
offer minor surgery sessions a GP had to be
included on the health authority’s minor surgery
list. A GP was able to treat his or her own patients
or those of partners or group members. The 
types of surgical procedure for which claims could
be made under the new contract are listed in
Table 1.
This part of the 1990 contract changes was
cautiously welcomed by GPs and generated debate
about equipment, training and quality control.8–13
Within 5 years of the contract being launched,
around 90% of GP principals in England and
Wales were accredited by their local health
authority as providers of minor surgery, and were
claiming for the maximum number (60) of
remunerable procedures per annum. This activity
forms the vast bulk of GP-performed minor
surgery in routine practice, and has therefore
attracted the most attention from investigators
over the years since.14–16
Of note in Table 1 is that two categories of
procedure for which claims could be made include
procedures that do not utilise traditional surgical
techniques: injections (largely of joints and around
joints) and cautery (or cryosurgery). As discussed
later in this report, this had implications for both
the conduct of the trial and the development of
GP minor surgery over the course of the 1990s. 
Health Technology Assessment 2008; Vol. 12: No. 23
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Chapter 1
IntroductionUnresolved issues
Since the introduction of the 1990 contract, there
has been a significant increase in the volume of
minor surgery performed in primary care, but
little to suggest that care has been transferred
from secondary care to the GP’s premises.15
There has also been at times fierce debate about
the quality and appropriateness of management
decisions and clinical practices in general 
practice, focusing around two issues. First is the
accuracy of clinical diagnosis and consequent 
need for histological confirmation of diagnosis.
Associated with this is the second issue, the
technical quality of surgery performed, 
discussed most often in terms of incomplete
excision of malignant or premalignant
conditions.14,17–28 These debates are still
unresolved, owing to the absence of firm evidence
to support either view. What evidence there is
comprises descriptions of personal case series
from general practice, and audits of completely 
or incompletely excised lesions reported by
pathologists, with or without accurate diagnoses
being recorded on the pathologist’s request 
form. 
Leese and colleagues examined the effect of the
minor surgery contract in 1995.29 In their
conclusion they state, ‘There are many issues
which are…still of concern and of these, 
lack of appropriate skills and expertise are
foremost…In effect, the issues of quality and 
cost effectiveness have not been sufficiently
addressed.’
This study attempts to address these issues.
Introduction
2
TABLE 1 Minor surgery procedures defined in the 1990
contract
Category Includes
Injections Intra-articular 
Periarticular 
Varicose veins
Haemorrhoids
Aspirations Joints
Cysts
Bursae
Hydroceles
Incisions Abcesses
Cysts
Thrombosed piles
Excisions Sebaceous cysts
Lipomas
Skin lesions for histology
Intradermal naevi, papillomata
Dermatofibromata and similar
conditions
Warts
Removal of toenails
Curette, cautery and  Warts and verrucae
cryocautery Other skin lesions
Other Ligation of varicose veins
Removal of foreign bodies
Nasal cauteryObjective
The objective of this study was to determine
whether there is equivalence in the competence of
GPs and hospital doctors to perform a range of
elective minor surgical procedures, in terms of the
safety, quality and cost of care.
Aims
The aims were:
● To conduct a randomised controlled
equivalence trial of minor surgery in two
settings.
● To collect data on quality of surgery, patient
satisfaction, patient safety and cost of procedure
in two settings. 
● To consider data from this trial and from other
sources, to consider the implications for policy
and to make recommendations for future
research in this area.
Health Technology Assessment 2008; Vol. 12: No. 23
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Chapter 2
Objective and aims of the studyDesign
Project structure
This study comprised a randomised, controlled
equivalence trial comparing the quality of minor
surgery performed by GPs and hospital doctors
(surgeons and dermatologists). The primary
outcome measure was clinical quality and safety of
minor surgery, with secondary outcome measures
of patient satisfaction and cost-effectiveness. This
trial was designed to test the hypothesis that there
is equivalence in the competence of GPs and
surgeons to perform a range of elective minor
surgical procedures. An equivalence trial has the
primary objective of showing that the response to
two or more treatments differs by an amount that
is clinically unimportant. This is usually
demonstrated by showing that the true treatment
difference is likely to lie between a lower and an
upper equivalence limit of clinically acceptable
difference.30,31 An equivalence design was 
decided upon because of the situation pertaining
when this trial was designed, because of a lack 
of observational evidence that would have 
allowed either an expected difference in
performance in one set of practitioners over the
other, or the direction of that difference, to be
specified.
Figure 1 shows a range of possible results for an
equivalence trial, with confidence intervals around
each result. It should be noted that it is quite
possible to have results where the two treatments
being compared are, statistically, significantly
different from each other (all results except for the
central result), but are either still equivalent in
clinical importance (the two results to either side
of the central result) or are uncertain in
importance [the two results overlapping the
equivalence limits (marked – and +)]. Only the
two outermost results in Figure 1 are both
significant and clinically important. This makes
the interpretation of equivalence trials different
from that of straightforward treatment trials, but
in some ways more honest: many treatment
difference trials are reported as showing
‘significant differences’ without comment being
made on the clinical importance of results.
Health Technology Assessment 2008; Vol. 12: No. 23
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Chapter 3
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True difference
– + 0
Equivalent
Equivalent*
Equivalent
Uncertain
Uncertain
Not equivalent
Not equivalent
Range of equivalence
FIGURE 1 Equivalence trial: possible resultsSetting
The trial was performed in South Hampshire, the
geographical area lying between the New Forest
and Portsmouth and surrounding Southampton. 
Participants and inclusion criteria
All patients with one of a range of conditions
amenable to minor surgery, who presented to one
of the GPs participating in the trial and who were
considered suitable for treatment by an individual
GP or one of their partners, were invited to
participate in the trial. The trial recruited patients
over 2 years (2000–2002), from more than 40
practices throughout two health authority areas.
As discussed in Chapter 1, there are six categories
of treatment attracting payment. Of these, two
differ markedly from the others. The first is cautery,
activity within which is largely composed of
treatment for cutaneous warts, and for which a
recent systematic review confirmed little evidence 
of benefit.32 The evidence used in this review, albeit
not yet synthesised, was available in 1999/2000,
when the study design was being finalised. In an
equivalence trial it is possible for two treatments to
be judged as equivalent in terms of effectiveness,
and yet for both to be equally ineffective. This
clearly compromises the interpretation of the trial
result. On this basis it was decided to exclude this
category of treatment from inclusion.
The second treatment category differing markedly
from the others is injections, which is mainly
concerned with the treatment of painful joints.
Including joint injections in this trial was
considered, but it was concluded that outcome
measures for this category would be different from
those for the other categories of treatment
included and, moreover, would be specific to each
joint treated. A preliminary search of the literature
showed that for many joints these measures did
not exist in validated form, if at all. Inclusion of
joint injections would have rendered both design
and interpretation of the trial very complex,
therefore, and it was agreed with the HTA
Programme that this category of treatment should
not form part of the trial. All other categories of
treatment, however, could be judged in terms of a
common set of outcome measures. Included within
the trial, therefore, are surgical excisions, incisions,
ablations and aspirations of skin and subcutaneous
lesions, injection of varicose veins, and banding of
haemorrhoids.
Interventions
In formal terms the interventions were structurally
rather than clinically different, and comprised
elective minor surgery for the conditions 
described above, delivered in either a primary care
or a secondary care setting. In the primary care
setting the intervention could be delivered either
by the patient’s own GP or by referral to a
colleague within primary care. In secondary care
the interventions were delivered by either
surgeons or dermatologists at a variety of grades.
Both interventions mimicked the situation
pertaining in real life as much as possible, except
for the fact that specially organised clinics were 
set up in the hospital arm (see below for
explanation).
Sample size and outcome measures
Quality of treatment was initially defined as the
absence of complications resulting from the
surgery. The design of an equivalence trial and its
sample size depend heavily on the expectations of
the outcomes that will be achieved. There was very
little in the literature regarding the complication
rates that could reasonably be expected for minor
operations conducted in general practice. The
best available was from O’Cathain and colleagues,
who conducted a non-randomised comparison of
minor operations conducted in GP practices and
hospitals in Rotherham in 1989.33 They found no
statistical difference in indicators of complications
such as wound infection rates and other
complications between the GP and hospital arms
of the study. The overall rate of wound infections
and other complications was 11.4% in the hospital
group. This was used as the expected rate of
complications for the initial sample size
calculations in the present study, with a 50% each
way (±5.7%) range of equivalence.
Using the formula proposed by Makuch and
Simon, and specifying 5% significance and 90%
power for sample sizes, a sample size of 653
patients in each arm was obtained.30 This was
considered to be a large, but achievable,
recruitment target for this study. The number of
GPs taking part in the study was expected to be
large, as the project group had ready access to the
local primary care research network of GPs
[Wessex Research Network (WReN): 190 of these
GPs had already expressed an interest in taking
part in a study of this kind]. As each GP was
believed to have up to 60 eligible patients per
annum who could potentially be randomised into
the trial, recruiting slightly over 1300 patients did
not appear overambitious.
Secondary outcome measures were defined
initially as quality of surgery, patient satisfaction
and cost-effectiveness.
Methods
6Protocol revision
Upon starting recruitment it quickly became
obvious that the overall complication rate was not
as high as that experienced by O’Cathain and
colleagues in their study.33 Details of the
complications suffered by patients were collected
in the questionnaire developed for this study to
assess the patient experience with the treatment
process. The initial estimate, based on the first 50
questionnaires received from patients, was a
complication rate of less than 5%, although clearly
this was an estimate with wide confidence
intervals. Using the same 50% each-way
equivalence limits, however, this would have
inflated the required sample size to 1596 in each
arm, or 3192 patients in total. Whereas the
original estimate of 1306 patients needing to be
randomised had seemed achievable, more than
doubling that estimate did not, and the
researchers decided to investigate powering the
trial using other outcome measures. 
Since the trial hypothesis was that there is
equivalence in the competence of GPs and
surgeons to perform a range of elective minor
surgical procedures, the choice of outcome
measure to replace complications of treatment had
to remain within the sphere of operator
competence. This ruled out patient satisfaction
and cost, leaving wound scoring scales as the next
best alternative. 
Two tools are found in emergency medicine
literature from the USA. Quinn and Wells describe
the use and reliability of both a simple visual
analogue score (VAS) and a categorical scale for
the assessment of traumatic wounds, showing that
both produce good interobserver and
intraobserver reliability when assessing wounds
using photographs.34 Their categorical scale
(Table 2) has been shown to produce results that
show strong correlation with patients’ views of
their wounds.35 Although these scales and
measures were developed for assessing repairs to
traumatic lacerations, they have also been
validated for use in elective wounds36 and it was
decided to use them henceforward as primary
outcome measures; they were in any case already
in use as secondary outcome measures. This
change in protocol was discussed with and
approved by the commissioning body, the NHS
HTA Programme.
The VAS has a potential score from 0 to 100 in a
continuous distribution. The increased power
afforded by using a continuous measure to power
the trial, rather than an ordinally distributed one
which would require non-parametric analysis,
meant that it was the obvious choice to recalculate
sample size. The mean VAS for those patients who
had returned questionnaires by the time of
recalculation was 50.7 [standard deviation (SD)
17.3]. Using the formula provided by Machin 
and colleagues31 for calculating sample sizes for
equivalence studies utilising outcome measures
with continuous distributions, and specifying 5%
significance and 90% power, a sample size of 245
patients in each arm (490 in total) was obtained,
with 10% each way limits of equivalence (i.e. 50.7
± 5.07).31 This appeared achievable, and the trial
continued using this revised sample size.
Assessment of quality of surgery
Assessment of the wound was undertaken between
6 and 8 weeks postsurgery by two blinded
independent reviewers using digital photographs
of each wound. This was a pragmatic time interval.
The appearance of wounds has been shown to be
reliably correlated at 3 months and 1 year, whereas
the appearance at 5–10 days does not correlate
with 1-year appearance.37 However, 3 months was
felt to be too long an interval to allow accurate
recall of subjective impressions that the patients
were to be asked about in the assessment of
satisfaction, and might also have led to an
unacceptably large loss to follow-up rate in the
study. A time of 6–8 weeks postsurgery was felt to
be an acceptable compromise. Digital photographs
were taken of each wound by the trial nurse (some
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TABLE 2 Criterion-based score system for assessing wounds
Distortion of skin around the scar Score 0 if present  Score 1 if not present
Width of the scar Score 0 if > 2 mm Score 1 if < 2 mm
Step across scar Score 0 if present  Score 1 if not present
Edge inversion Score 0 if present  Score 1 if not present
Inflammation/discharge Score 0 if present  Score 1 if not present
Overall result Score 0 if not acceptable Score 1 if acceptable
Total score < 6 = suboptimal healing 6 = optimal healingpatients had more than one procedure
undertaken) using a Nikon D1 digital single-lens
reflex camera. It was planned that four
photographs would be taken of each wound: one
was taken from enough distance to allow the
reviewers to orientate themselves to which part of
the body had been treated; three close-up pictures
were then taken, one perpendicular to the wound,
one obliquely to the wound and a final picture was
taken with the camera at a fixed distance from the
wound. This series of photos was designed to allow
the reviewer to assess the wounds using both the
VAS and the categorical scale. 
Photographs were judged separately by two
observers, one a consultant surgeon, and one a GP
with surgical training. They were both blind to the
arm of the trial, and neither of them undertook
any of the trial surgery. The photographs were
presented to the reviewers in a specially written
form program based on a Microsoft Access
database, allowing simple completion
(Appendix 1). The assessors judged each set of
photographs using both wound scoring scales
(VAS and categorical) at the same time. Their
scores were combined for analysis.
Patient satisfaction
No satisfactory measure of patient satisfaction
existed for this group of patients that had been
validated and that contained questions on all the
areas upon which data were to be gathered, and it
was decided to construct a questionnaire
specifically for the purpose as part of an MSc
project.38 A search of the literature and two group
interviews with minor surgical patients generated a
comprehensive list of issues to be covered within
the questionnaire. From these issues items with
Likert responses were formed. The literature,
patient and expert opinion contributed to face
and content validity. The final questionnaire used
in the study forms Appendix 2. 
Pathological diagnosis
Pathological diagnosis was considered important as
the issue of appropriate treatment of both benign
and malignant lesions was much debated in the
early years after the introduction of the fee-for-
service payments for minor surgery. The authors
attempted to obtain a pathology report for every
operation if there was one available, a detailed
search being made. All the histology services for
the hospitals and GP practices participating in the
study were provided by three pathology
departments (Southampton University Hospitals,
Salisbury District Hospital and Portsmouth
Hospitals). The majority of the reports came from
Southampton University Hospitals Trust (SUHT)
and were obtained directly from the results service
within the hospital. Those from the other centres
were obtained via the GPs involved. Where missing,
the individual patient records were searched at the
GP practice and the hospital results service
approached. Only when this process was exhausted
was it assumed that a specimen had not been sent.
This process was repeated several times after
completion of recruitment and initial follow-up
had been completed. The referring diagnosis was
compared with the final report, the pathologist’s
report taken as being correct. For malignant
lesions, completeness of excision was noted.
Analysis
As well as the effect of the trial arm upon outcome,
individual operator effects have to be taken into
account in both arms of the trial, and so does the
effect of patients having more than one lesion
removed during the trial. The resulting data set is
hierarchical in nature, therefore, with three levels
for variables measuring quality of surgery at lesion
level (trial arm, operator, lesion) and two levels for
questionnaire variables (trial arm, operator).
The primary outcome (VAS) is a continuous
variable. A clinically important difference in VAS
score was defined as 10% of the overall mean VAS
score either way from zero (no difference). This
clinically important difference was used to define
an upper and a lower equivalence limit around
zero. If the 95% confidence interval (CI) around
the observed difference in VAS score lay
completely above the upper equivalence limit, or
completely below the lower equivalence limit, then
the performance of the operators in the two arms
was to be judged non-equivalent: if it lay entirely
between the two equivalence limits it was to be
judged equivalent: if it straddled either equivalence
limit, the result was to be judged uncertain. The
mean difference and 95% confidence intervals
around it were calculated using the MIXED
procedure in SPSS 14.0, with trial arm specified as
a fixed effect, and operator and patient (to
account for multiple lesions) as random effects.
This was a per-protocol analysis, this being an
equivalence trial.
For other trial outcomes no prior hypothesis was
made to enable generation of equivalence limits.
Methods
8Outcomes are therefore reported simply as mean
differences (or differences in proportions) and
confidence intervals. For these outcomes
intention-to-treat (ITT) analysis was undertaken,
making a worst case assumption for each missing
data item. For the categorical quality scale the
proportion in each trial arm achieving maximum
score from both assessors on quality scale (i.e.
12/12) was calculated, as was the mean score for
each trial arm on a scale comprised of adding
both assessors’ assessments together for each case.
Scales derived from questionnaire items were
treated in a similar fashion to assessed quality
scales. Certain items (e.g. median distance
travelled to surgery) were not amenable to
multilevel adjustment and have been reported as
they stand. 
Training of GPs and quality of
surgery
To try to estimate the effect of training on GPs’
abilities to undertake minor surgery an analysis
was also undertaken comparing the VAS scores
from scars resulting from those who had received
formal ‘in-post’ surgical training and those who
had not. Details of amount of training undergone
by GPs in surgical techniques were collected in a
separate questionnaire survey. A questionnaire was
distributed to all GPs in South Hampshire asking
for details of jobs undertaken in surgery,
dermatology or obstetrics and gynaecology,
possession of FRCS (Fellow of the Royal College 
of Surgeons) or equivalent [e.g. Member of the
Royal College of Obstetricians and Gynaecologists
(MRCOG)] and attendance at other training
courses. The results of the whole survey are 
largely not pertinent to the trial or its
interpretation, and will not be presented in full.
For the purposes of this analysis results of
individual questions were combined to give a
classification in in-post or informal training
undergone. This classification was then applied to
operators in the trial and their results in terms of
surgical quality were compared.
Participants
General practitioners
It was originally planned to recruit members of
the WReN to take part in the project. When this
study was undertaken, WReN was an active
organisation, primarily of GPs, promoting and
developing both research ideas and projects in
primary care in the Wessex region of the NHS
(Dorset, Hampshire, the Isle of Wight and
Wiltshire). However, for logistic regions, it was 
not possible to use this network in the way
envisaged because of the organisation of hospital
services in the region. The project had to be
limited to the areas in which there was ready
access to a hospital service for providing minor
surgery to patients randomised to the hospital arm
of the study. It proved impossible to persuade
some hospital trusts of the benefits to them of
entering the trial at all, and it was equally
impossible to persuade others that they should
treat patients randomised to the hospital arm but
who were resident in other catchment areas. This
resulted in setting the catchment area for the trial
as (initially) the bulk of the Southampton and
South West Hampshire health authority area. This
was subsequently extended to the western areas of
the Portsmouth and South East Hampshire health
authority. 
Hospitals
Recruiting hospitals to take part in the study was
difficult. When the initial application was made to
the HTA to conduct the study, the relevant senior
managers in the principal hospital trust (SUHT)
had agreed to support the study. However, there
was a long gap between initial application for the
grant and starting the project (3 years). During
this time the funding arrangements for research
within the NHS evolved rapidly following the
adoption of the principles described by Culyer.39
This review of research funding mechanisms
assigned research costs, service costs and
treatment costs to three separate fund-holding
bodies. Definitions provided in the review were
not tight enough, and this led to inevitable
differences in interpretation. Lack of agreement
on what constituted ‘service’ and ‘treatment’ costs,
and what differentiated one from another, led to
protracted discussions with SUHT, the likely major
host for the hospital arm of the trial. The issue
centred on the requirement to set up a special
operating list for the purposes of the trial. This
was necessitated by the very long hospital waiting
lists for minor surgery for non-malignant skin
lesions at Southampton, which would have meant
that most, if not all, patients randomised to this
arm would not have had a procedure undertaken
within the timespan of the trial, had they been
assigned to routine hospital care. Although this
would have provided a definitive result as to the
feasibility of undertaking all minor surgery in a
hospital setting (at least under current financial
constraints), it would not have answered questions
relating to quality or patient experience of actually
having surgery. Altogether, these delays
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which was agreed by the HTA.
These same problems came to the fore when
attempts were made to extend the trial recruitment
area to Portsmouth in 2000/01. At that time, the
dermatology and general surgery consultants in
Portsmouth who specialised in treating skin lesions
had a waiting time of 11 months for low-grade
skin cancer surgery, and had stopped offering any
service for non-malignant skin lesions. In
addition, internal funding arrangements for
pathology services in Portsmouth meant that each
lesion sent for pathological analysis would be more
expensive to the clinical budgets of the operating
consultants than in Southampton. Portsmouth
Hospitals Trust was also in receipt of a far smaller
Service Increment for Teaching and Research
(SIFT-R: the research funding grant given to
hospital trusts) allocation as a trust than that given
to SUHT, as a result of the teaching hospital status
granted to Southampton.
These problems were not as acute in the
Southampton Community Health Services Trust,
which runs most of the smaller scale hospitals in
the Southampton district. Their waiting lists were
shorter, and generally there was less pressure on
each list. The overall numbers predicted to need
treatment in the community trust facilities were
also much smaller, only 20% of the total number
of patients recruited to the hospital arm of the
study. Once the practicalities had been decided of
how to make appointments in the units involved,
there were no significant further problems in
supporting the trial in these locations. Similarly,
these problems were not an issue when the armed
services hospital at Haslar in Gosport was
approached. Here, the practical difficulty of
predicting when consultant surgeons or their
teams would be available to perform procedures
was more important.
The hospitals and trusts that agreed to take part
in the study, finally, were the Southampton
University Hospitals NHS Trust, the Southampton
Community Health Services NHS Trust, and the
Royal Hospital Haslar, Gosport. The community
trust made available facilities at Romsey Hospital,
Lymington Hospital, The Fenwick Hospital,
Lyndhurst Hospital and Hythe Hospital. The
university hospitals trust made available facilities
at the Royal South Hants Hospital. The study was
supported directly by the use of staff from
academic and NHS staff in general surgery,
dermatology and pathology, within all of the trusts
and institutions mentioned. In terms of numbers
of hospital doctors directly involved, 59 performed
procedures for the study.
Recruitment
Recruitment of patients to the trial was by GPs in
their surgeries on an opportunistic basis. It was
necessary initially to approach GPs to ask them to
participate in the trial.  All GPs in the area were
contacted by letter, this being followed by a letter
to their practice manager. The intention was to
arrange a direct presentation with the GPs about
the reasons for the study and the practical
arrangements for taking part in it.
Financial issues
The challenges of negotiating Culyer funding were
not the only financial issues to impact upon this
trial. As described, GPs receive payment for their
minor surgery activity. In the Southampton and
South West Hampshire health authority area more
than 90% of GPs were registered as providers of
minor surgery. They were entitled to claim £25.65
for each procedure undertaken, up to a total of 60
procedures per annum (1999/2000 rates), a total
of £1539 per year. Theoretically, therefore, a GP
could lose a significant amount of money by
taking part in the trial; if the demand for minor
surgery from their patients in a year amounted to
only the 60 patients on whom they would have
been entitled to claim, approximately 30 would be
sent to hospital for their treatment. They would
not be able to claim the fee for these patients, thus
losing £769.50 in fees for their practice.
In order to remove this disincentive to take part, a
means had to be found to compensate the GPs for
their potential loss of earnings. However, the
internal rules for the NHS and for supporting
clinical research meant that it was not possible
simply to pay the fee for patients randomised to
hospital to the GP from trial funds. A compromise
was found such that GPs received a payment to
cover their costs in taking part in the study;
principally, the time that it took them to complete
the minimal paperwork for the recruited patients.
This allowed for a payment of £21.75 per patient
recruited to the GP. This was funded by additional
monies allocated from the National Co-ordinating
Committee for the HTA Programme. This sum
ensured that the GPs would receive slightly more if
they recruited patients to the study than if they
simply operated on them themselves, without
there being such a large financial inducement that
patients would be recruited who did not need
operations.
Methods
10Patient route through the trial
The trial process was designed to be simple and
efficient for both GP and patient. GPs were given a
ringbinder file with information and instructions
about the trial and, within each, a number of
recruitment packs. The packs contained the
paperwork required to complete the recruitment
of each patient, this was: a reminder of the
inclusion/exclusion criteria for the study, an
information leaflet for the patient, a recruitment
pro forma and a sealed envelope containing the
randomisation allocation to hospital or GP
treatment.
When a patient presented to a participating GP
with a condition suitable for randomisation, the
GP asked for their informed consent for
recruitment to the trial. If consent was obtained,
randomisation to one or other arm of the study
was performed by means of opening a sealed
envelope which contained a card containing
details of trial arm. Details of the patient, their
diagnosis and randomisation were then faxed to
the trial office. If they were randomised to
hospital, the trial office arranged for treatment at
an appropriate venue; if they were randomised to
general practice, the GP was responsible for
notifying the trial office of the date for the
procedure. A special treatment list was provided by
SUHT to allow rapid treatment of trial patients in
the hospital sector. This clinic mimicked normal
hospital service in all respects other than the time
taken to be treated in it. All patients randomised
to the hospital arm of the study were seen and
treated within 21 days of entering the study, unless
the patient opted for a later appointment. The
trial office arranged and conducted all follow-up
related to the trial, usually meeting the patient at
a time convenient to them, in their own home, in
their GP practice or in another convenient place,
to enable photography and for the patient to
complete the patient satisfaction questionnaire.
Randomisation
A computer-generated sequence of random
allocation to hospital or general practice was
obtained from the Public Health Sciences and
Medical Statistics Group at the University of
Southampton. The numbers were randomised in
blocks of six, a detail that was withheld from the
GPs using the envelopes. A series of envelopes was
made up, each with a sequential number on the
outside, and a sticker with ‘Hospital’ or ‘GP’
placed inside. The envelopes were manila, and
therefore it was not possible to read the allocation
without opening the envelope.
The envelopes were put in sequence into the
patient recruitment packs given to the GPs. Thus
each GP would have, in the ringbinder, ten packs
with envelope numbers that ran consecutively.
Once a patient was recruited to the trial and had
signed the consent form, the randomisation
number was recorded by the GP on the
recruitment pro forma and the GP then opened
the envelope. They then recorded the treatment
allocation onto the pro forma, sent this to the trial
office and, if the patient was randomised to
general practice, proceeded with making the
arrangements for the procedure to be carried out. 
The randomisation number was checked against a
list kept in the trial office, to confirm that the
reported randomisation was that which would be
expected from that envelope, and that envelopes
were being used in sequence by GPs. This system
worked well during the trial. On one occasion the
randomisation was not what was expected from
the envelope numbers. After having checked with
the GP concerned that they had been used in the
correct order, the error was found to have been
with putting the wrong randomisation stickers in
the envelopes in that batch. That batch of
recruitment packs was withdrawn from the GP
involved, and a new one issued. There were no
further problems of this sort with the process of
randomisation.
Blinding
Clearly, it was not possible to blind patients to
which arm of the trial they had been allocated.
However, blinding of the two independent
observers undertaking assessment of wounds was
undertaken. Since all photographs of wounds 
were taken some 6–8 weeks after surgery, and
often in the patient’s own home, it was not
possible to tell from them where treatment had
been undertaken.
Patient withdrawal protocol
A patient could be withdrawn from the study for a
number of reasons:
● At all stages within the study, the patients
themselves could elect to withdraw from the
trial, without compromising their ongoing care
with the doctors involved in treating them.
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condition with which they had presented had
resolved, or they no longer wanted it treated. 
● More complex rules had to be established for
the study for lesions or conditions where the
decision to treat by surgery might be questioned
by the doctor asked to perform the surgery.
There were two situations where this could
occur. The first was where a patient was
randomised to treatment in general practice,
within a practice where one or two partners
performed the minor operation for their
colleagues. Although appropriately recruited by
another GP, the operating GP had the right to
decline to treat, usually on the basis that the
lesion was sited in a more difficult area, for
example the face or over a joint, and that
therefore they were not happy to proceed. The
second situation was when a patient had been
randomised to hospital for treatment, and the
opinion of the hospital doctor concerned was
that the lesion had been misdiagnosed in
general practice and needed either more
radical treatment than could be offered in the
clinic or day theatre concerned, or other
investigation before treatment.
Record-keeping
The mainstay of the record-keeping for this study
was a database written in Microsoft Access 2000
for this study. It incorporated reports that allowed
tracking of patients through the study; generating
due lists of operations that were pending, follow-
up appointments that were pending and lists of
outstanding paperwork. It also enabled
monitoring of recruitment rates and sites,
comparison with actual and expected
randomisation, and dropout rates from the study.
Most importantly, it allowed digital storage of
photographs and assessment of wounds. The
database and photographs were maintained on
University of Southampton mainframe computers,
behind electronic firewalls allowing limited access
with passwords. This proved a secure and
confidential way of maintaining the records. The
paper record for the study was minimised,
consisting of a patient recruitment pro forma, a
consent form, an operation summary and, when
applicable, a copy of the pathology report for each
procedure. These were kept in the secure trials
office in the University Department of Surgery
within Southampton General Hospital.
Methods
12Potential recruitment population
It is important for the completeness of the
Consolidated Standards of Reporting Trials
(CONSORT) statement for a trial of this sort that
an estimate is made for the total number of
patients that could potentially have been
recruited. From the data obtained from GPs
throughout the area presented elsewhere in this
report, the numbers of patients can be estimated
that are treated with eligible procedures. GPs in
Southampton and Portsmouth area health
authorities perform an average of 20.12 (SD 28.9)
excisions per year.
In total, 170 GPs agreed to take part in the study,
of whom 82 referred at least one patient, 
although the number of patients contributed
varied widely, ranging from a single patient
(n = 16) to a maximum of 28 patients (with 
41 lesions between them). The trial recruited 
for 2 years, but not all practices were active
recruiters throughout this time. A reasonable
estimate would be that they recruited for an
average of 1 year.
Using these figures for 170 GPs gives an estimate
of 3420 eligible patients. Repeating the calculation
using only 82 GPs, the number who actually
recruited any patients, gives an estimate of 1695.
A pragmatic average of 2500 was made for the
total number of eligible patients that might have
been recruited to the study.
Recruitment
Eighty-two GPs referred one or more patients to
this study: 568 patients were recruited to the trial
(284 primary care, 284 hospital). The basic
demography of the participants and pathology of
lesions as judged by referring GPs are given in
Table 3. The arms are similar in age, gender
distribution and diagnosis. A CONSORT diagram
appears in Appendix 3. Twenty-three cases in the
primary care arm and 26 in the hospital arm did
not attend for surgery or were excluded because
they were unsuitable for surgery in primary care or
ineligible to enter the trial.
Types of lesion presenting and
procedure undertaken
Altogether, referrals were received for 705 lesions.
There is evidence that 637 skin procedures plus 17
ingrowing toenail procedures were performed,
based on the presence of photographs of the
operation scar, completed questionnaires,
histological samples or documentation (313
primary care, 341 hospital). Of those not receiving
surgery one case died before surgery, in 17 cases
the lesion resolved (e.g. ‘fell off ’) or required only
reassurance, in eight the lesion or subject was
either judged unsuitable for surgery in general
practice or was ineligible for the trial (three of
these were referred urgently to hospital specialist
surgery), and in 26 cases ‘did not attend’ is all that
is recorded. In 589 cases assessable pictures
resulted [273 primary care (87%), 316 hospital
(93%)]. Sixty-five GPs undertook surgery in the
primary care arm of the trial and 60 hospital
surgeons or dermatologists in the hospital arm.
Excisions of skin lesions were the most numerous
procedures undertaken, the remaining categories
making up less than 10% of the total. 
VAS scores of quality of surgery
The overall VAS score across all trial subjects was
59.8, generating 10% each-way equivalence limits
of ± 5.98. The VAS score in the hospital arm was
61.22, and in the primary care arm 55.76 (mean
difference 5.46, 95% CI 0.925 to 9.990). Figure 2
shows a graphical representation of the result and
makes it clear that while there is a statistically
significant difference in VAS scores, it is an
uncertain result rather than a non-equivalent one. 
Categorical quality scores
In the hospital group 66/341 lesions (19.4%)
achieved a maximum score on the categorical
scale, compared with 40/313 (12.8%) in the
primary care group [odds ratio (OR) 1.64, 95% CI
0.997 to 2.69].
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TABLE 3 Demography of trial participants, and number of lesions referred (number where procedure performed) into the trial as
diagnosed by referring doctor, by trial arm
Hospital group Primary care group
(n = 284) (n = 284)
Mean age (years) 47.8 49.7
Number (%) of females 159 (56%) 150 (53%)
Total lesions referred (procedure performed) 369 (341) 336 (313)
Unknown/non-specific description 7 (7) 7 (7)
Eczema/dermatitis 0 0
Granuloma 5 (4)  3 (2) 
Solar elastosis 0  0
Ingrowing toenail 10 (9)  8 (8) 
Sebaceous gland hyperplasia 0 1 (1)
Skin tag, fibroepithelial polyp, skin polyp 21 (20) 37 (35) 
Chondrodermatitis nodularis helices 0 0
Viral warts 5 (5) 7 (7) 
Scars including keloid 1 (1) 1 (1) 
Benign tumours including neurofibroma 14 (13) 18 (17) 
Lipoma 9 (7) 10 (10) 
Cysts including epidermoids 95 (90) 62 (53) 
Lentigo 0 0
Seborrhoeic keratosis, seborrhoeic wart, basal cell papilloma 85 (79)  63 (53) 
Melanocytic naevus 78 (72) 81 (78) 
Solar keratosis 2 (2) 2 (2) 
Cutaneous horn 0 1 (1)
Bowen’s disease 1 (1) 0
Basal cell carcinoma 25 (21)  26 (24) 
Keratoacanthoma 3 (3) 1 (1)
Squamous cell carcinoma 4 (3) 4 (4)
Malignant melanoma 1 (1) 3 (1)
Missing diagnosis/not referred by GP 3 (3) 1 (0)
Difference in VAS scores
–5.98 +5.98 0
Range of equivalence
0.93 9.99
5.46
Observed difference
FIGURE 2 Pictorial representation of VAS score results showing observed difference with 95% CIs and equivalence rangePatient satisfaction
A total of 467 subjects returned questionnaires
(228 GP arm, 239 hospital arm), although not
all subjects answered all questions. Table 4 presents
patient satisfaction scores for five domains (with
number of items in domain) and eight individual
items in each trial arm. All scores have a
maximum range from 1 to 5. For all scores a low
score reflects greater patient satisfaction. There
are few significant differences between arms,
except in matters relating to convenience and
knowing the doctor, where the primary care arm
has lower scores than the hospital arm. The
hospital arm scored better on provision of
information following the operation. 
Patient access to care
Table 4 also presents questionnaire-derived items
related to access to care, which all favour
treatment in primary care.
Later complications of surgery
Table 5 shows questionnaire-derived results for
problems following surgery. Although postoperative
wound infection was significantly lower in the
hospital arm there was no difference found in the
overall problem rate following surgery. 
Pathology reports
Overall, 491/637 skin procedures (77%) generated
a traced pathology report. Only 213/305 (70%) 
of GP skin procedures produced a pathology
report, compared with 278/332 (84%) in the
hospital arm [2 = 17.38, degrees of freedom 
(df) = 1, p < 0.001]. 
Completeness of excision of
malignant lesions
Completeness of excision was achieved in 15/20
malignancies (75%) in the hospital arm and 7/16
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TABLE 4 Patient satisfaction scores with mean differences and 95% CIs for the two trial arms using ITT analysis and the MIXED
procedure in SPSS 14.0: ITT analysis
Domain (number of questionnaire items) Hospital group Primary care group Mean difference
(n = 258) (n = 261) (95% CI)
Care and courtesya (4) 1.872 1.921 –0.049 (–0.322 to 0.225)
Satisfaction with wounda (3) 3.062 3.099 –0.037 (–0.273 to 0.198)
Privacy and comforta (2) 2.327 2.466 –0.138 (–0.39911 to 0.123)
Feeling that procedure was rusheda (2) 2.184 2.150 +0.034 (–0.228 to 0.296)
Worry that lesion was more serious than stateda (2)  2.050 2.182 –0.132 (–0.348 to 0.084)
Ease of making appointment (1) 2.261 2.058 +0.203 (–0.055 to 0.461)
Pain during operation (1) 2.517 2.371 +0.146 (–0.153 to 0.445)
Not kept waiting (1) 2.741 2.244 +0.496 (0.177 to 0.816)
Information following operation (1) 1.951 2.204 –0.253 (–0.478 to –0.028)
Confident to have similar operation in the future (1) 1.968 1.998 –0.030 (–0.309 to 0.249)
Importance of meeting doctor in the past (1) 3.249 2.694 +0.556 (0.290 to 0.822)
Pain in week after operation (1) 2.807 2.696 +0.111 (–0.153 to 0.375)
Wound irritating (1) 2.448 2.464 –0.016 (–0.286 to 0.255)
Items not adjusted for clustering by operator
Median distance travelled to have procedure done  5 2 +3 (3 to 4.25)
(miles) (1)
Median time waited after arrival and before treatment  45 10 +35 (35 to 50)
(minutes) (1)
Median time taken in total (minutes) (1) 135 60 +75 (60 to 90)
Trouble parking if came by car (1) 58/214 (22.5%) 39/220 (14.9%) 9.4% (1.5 to 17.1)
(44 NA) (41 NA)
A low score reflects greater patient satisfaction.
NA, not applicable.
a Domain.(44%) in the primary care arm of the trial
(2 = 3.65, df = 1, p = 0.056). However, two of
the three cases referred for specialist surgery in
this trial were malignant in character upon arrival
at hospital. If the assumption is made that they
received adequate excision from specialist surgical
intervention, this would result in revised figures of
17/22 (77%) completely excised in the hospital
arm and 7/16 (44%) in the primary care arm of
the trial (2 = 4.47, df = 1, p = 0.034).
Training of GPs and results in
terms of quality of surgery
Of the 65 GPs who undertook procedures in this
trial 48 (74%) returned the questionnaire; together
they carried out 278 of the 337 GP procedures
(82%). None possessed FRCS or equivalent.
Twenty-six (54%) had worked for 6 months or
more in a surgical or equivalent post (158
procedures) and the remainder had informal or
no specific training (120 procedures). Table 6
compares VAS scores in the two groups.
Clearly, the result, that those in the ‘informal’
groups score better than those in the ‘in-post’
group, is the opposite of what might be expected.
The obvious explanation is selection bias (i.e. that
those with more surgical experience are prepared
to tackle more complex procedures), but without
the benefit of a scoring system to allow procedures
to be graded by complexity it was not possible 
to investigate this further. Consequently, no
further analysis was undertaken comparing these
groups.
Results: quality of surgery and patient satisfaction
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TABLE 5 Number (%) of respondents to questionnaire reporting complications of surgery in each arm, with ORs (95% CIs) calculated
using logistic regression analysis adjusted for clustering by operator in Stata 9.0: ITT analysis
Hospital group (n = 258)  GP Group (n = 261) OR (95% CI)
Wound infection 31 (12.0) 50 (19.2) 0.58 (0.36 to 0.91)
Discomfort 62 (24.0) 58 (22.2) 1.11 (0.70 to 1.75)
Bleeding 52 (20.2) 64 (24.5) 0.78 (0.54 to 1.12)
Allergy 26 (10.1) 38 (14.6) 0.66 (0.39 to 1.12)
Other problem 53 (20.5) 70 (26.8) 0.71 (0.48 to 1.04)
No problems 116 (45.0) 123 (47.1) 0.91 (0.62 to 1.33)
TABLE 6 Comparison of VAS result in GP operators according to level of surgical experience
In-post group Informal group Mean difference 95% CI for difference
(n = 158) (n = 120)
Mean VAS score  52.02 60.46 –8.44 –0.426 to –16.457T
wo cost-effectiveness analyses are reported.
The first uses the original primary outcome
measure: absence of problems following surgery.
The second uses the completeness of excision of
malignancies removed. 
Cost of minor surgery
Patient-level resource-use data were not collected
alongside the MiSTIC trial, and in order to
produce a cost-effectiveness analysis it was
necessary to attach costs to each patient in the
hospital and GP arms of the trial. To do this, two
cost distributions were simulated, using the NHS
reference costs for minor surgery in hospitals and
primary care, respectively. Following convention, it
was assumed that the costs were log-normally
distributed. The NHS reference costs report the
mean and interquartile range (IQR).40 It is
possible to extract the standard deviation from the
IQR (Table 7). The mean and the standard
deviation are sufficient to parameterise the 
log-normal distribution. The distributions are
shown in Figure 3.
Monte Carlo simulation was then used to generate
samples of costs. One-thousand simulations were
generated for GP and hospital minor surgery
costs. SPSS was then used to select randomly the
appropriate number of cost observations from
each sample and allocate a cost to each subject 
in each arm of the trial. The Monte Carlo
simulations were generated using the Crystal Ball
Add-in for Microsoft Excel.41
This process of generating costs draws on the
between-centre variation in costs, which is
described by the NHS reference costs, rather than
the within-centre variation in costs that is normally
captured in sample cost data. Its use for this
evaluation can be thought of in terms of randomly
sampling trusts from across the NHS to provide
the care. 
Incremental cost-effectiveness
ratio
The primary result of cost-effectiveness analysis is
the incremental cost-effectiveness ratio (ICER).
This is calculated as the difference in the mean
effect in each group divided by the difference in
mean cost in each group.
Sensitivity analysis
It is now good practice to address explicitly the
uncertainty regarding the true population values
of the cost and effect parameters.42 Although one-
way sensitivity analyses may provide some insight
into the potential importance of this uncertainty,
probabilistic sensitivity analysis is the most
appropriate method of incorporating the
uncertainty across all the parameters into the
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Chapter 5
Economic analysis of trial
TABLE 7 Costs of hospital and GP-based minor surgery
Mean cost (£) SD
Hospital-based minor surgery 1222.24 23.24
GP-based minor surgery 449.74 47.74
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FIGURE 3 Sampling distributions for (a) hospital and (b) GP
minor surgery costsEconomic analysis of trial
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results of an economic evaluation.43 Conventional
frequentist analysis often uses the confidence
interval to characterise uncertainty. However, a
95% confidence interval does not give you a range
within which you are 95% certain the true value
lies. Rather, it tells you that if you were to repeat
the experiment 100 times and calculate the
confidence interval on each occasion, in 95 of
those analyses the true value would lie within the
calculated range and on five occasions it would
not. It provides no information about whether the
result you are analysing is one of the 95 or one of
the five. In contrast to this, the Bayesian approach
to characterising uncertainty, which is taken here,
gives the degree of belief or probability that
something is true.
The bootstrap was used to construct probability
distributions for the population mean costs and
outcomes for patients treated in hospital or by
GPs.44 The basic idea of the bootstrap involves
repeated random sampling with replacement from
the original data sets to produce random samples
of the same size as the original sample, each of
which provides an estimate of the parameters of
interest.45 In this case, it was used for mean costs
and mean effects. ‘With replacement’ means that
any observation can be sampled more than once
in each bootstrap sample. 
Incremental costs and outcomes were calculated
for each bootstrapped simulation and plotted on
the incremental cost-effectiveness plane.46 This
was repeated 10,000 times, and these 10,000
simulation results used to construct a cost-
effectiveness acceptability curve (CEAC).47 A
CEAC plots the probability that an intervention is
cost-effective as the decision-maker’s willingness to
pay for an additional unit of effect increases. In
this analysis the CEAC plots the probability that
hospital-based minor surgery is cost-effective
compared with GP-based minor surgery, as the
decision-maker’s willingness to pay to avoid a
missed diagnosis of malignancy increases.
Discounting
All events considered in this evaluation occurred
within 1 year and therefore, by convention,
discounting was not required.
Results
The mean cost (SD) for hospital-based minor
surgery was £1222.24 (£23.24) and for primary
care £449.74 (£47.74). The mean difference in
effect between the hospital and GP surgery in
terms of the patient-reported ‘no problems
following the operation’ outcome was 0.0135 in
favour of hospital surgery. The mean cost
difference between hospital and GP surgery was
£770.77.
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The expected ICER was £13,558 per additional ‘no
problems following operation’ for hospital surgery
versus primary care surgery (SD 631,878). Figure 4
plots the CEAC for hospital versus primary care
surgery. The vertical axis indicates the probability
that hospital minor surgery is cost-effective. There
is no plausible willingness to pay for which primary
care is expected to be cost-effective. However, there
remains a large amount of uncertainty around both
the expected difference in costs and outcomes
using this measure of effect.
At £33,800, the mean ICER per additional
complete excision is high, as is the standard
deviation (697,170). The uncertainty around 
the ICER is clustered around the origin, 
meaning that the ICER is not very stable, 
and small changes in either the incremental 
costs or effects will lead to large shifts in the 
ICER. The CEAC is well behaved and easy to
interpret (Figure 5). As the value of an 
incomplete excision avoided approaches 
£13,000, the probability that hospital surgery 
is cost-effective becomes stable at around 90%.
Given the potential health consequences of an
incomplete excision of, say, a malignant
melanoma, this appears a cost-effective 
option.
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T
his study was not powered to investigate
pathological outcomes, and the resource to
allow proper follow-up of clinical outcomes (e.g.
survival following diagnosis of malignant
melanoma) was not available. However, many
procedures in this trial resulted in a pathology
specimen being sent, and the decision was made
to investigate the nature of lesions sent for
pathology, the accuracy of their diagnosis and the
completeness of excision of malignant lesions. 
Data
All patients recruited to the MiSTIC trial had a
GP referral form indicating a working diagnosis
for the lesion concerned. Details from these were
entered into a database, along with the
histological diagnosis found on the histology form
pertaining to the sample, where one was found.
There were many diagnoses on the referral forms
and pathology reports, and they were divided into
23 categories for analysis, using a classification
derived from Rook’s textbook of dermatology, Sixth
edition.48 The categories arrived at are shown in
Table 8.
Analysis
Chance-corrected inter-rater reliability was
measured using Cohen’s kappa in Stata 8.0 (Stata
Corp.). A kappa value greater than 0.75 is
considered excellent agreement beyond chance,
values below 0.40 represent poor agreement, and
values between 0.40 and 0.75 represent fair to
good agreement.49 An initial comparison between
GP diagnosis and histological diagnosis was
undertaken across 22 of the 23 categories
(ingrowing toenails were excluded from this
analysis). For cases where a procedure was known
to have been performed but where no histology
report was recovered a sensitivity analysis was
undertaken assuming, first, no agreement over
missing cases and, second, complete agreement
over missing cases. The 22 categories were then
collapsed into two categories, benign and
malignant, and kappa was recalculated. The
‘malignant’ category comprised three
malignancies (malignant melanoma, squamous cell
carcinoma and basal cell carcinoma) and one
premalignant condition (Bowen’s disease). Using
this dichotomous categorisation the sensitivity,
specificity and positive predictive value for GPs’
Chapter 6
Comparison of GP diagnosis and histopathology of 
lesions, and performance regarding recognition 
of malignant lesions
TABLE 8 Categories used to classify diagnoses by histology
Category  Type of skin lesion Category  Type of skin lesion
1 Unknown  13 Cysts including epidermoids
2 Eczema/dermatitis 14 Lentigo
3 Granuloma 15 Seborrhoeic keratosis, basal cell papilloma
4 Solar elastosis 16 Naevi
5 Ingrowing toenail 17 Solar keratosis
6 Sebaceous gland hyperplasia 18 Cutaneous horn
7 Skin tags, fibroepithelial polyp, skin polyp 19a Bowen’s disease
8 Chondrodermatitis nodularis helices 20a Basal cell carcinoma
9 Viral warts 21 Keratoacanthoma
10 Scars including keloids 22a Squamous cell carcinoma
11 Benign tumours including neurofibroma 23a Malignant melanoma
12 Lipoma
a Malignant.recognition of skin malignancies were calculated
with 95% confidence intervals. Lack of any
estimate of malignancy among missing cases
rendered it difficult to make assumptions that
would have allowed a sensitivity analysis on the
dichotomised data, and this was consequently not
done.
In the group of malignancies where surgery was
undertaken by the GP, cross-tabulation was used to
examine whether recognition of the lesion as
malignant had an effect on completeness of
excision.
Results
Of 705 lesions referred into the original study, 654
can be shown to have been subject to a procedure,
17 of these being ingrowing toenails in which
histology is not usually performed, and which were
excluded from analysis. Overall, 491 of the 637
skin procedures (77%) generated a traceable
pathology report. Table 9 shows numbers of these
cases by histological category as described by GPs,
and number in each category where a histological
sample was found by trial arm. In one case there
was no referral from the GP, the procedure having
been performed at the request of a patient with
multiple lesions and in whom that lesion had not
been mentioned in the referral. This lesion was
excluded, leaving 490 for further analysis. 
The table demonstrates that the deficit in 
samples does not follow a random pattern; 
while it might be expected that skin tags would 
be underrepresented, shortfalls in other categories
(e.g. basal cell papillomata, melanocytic naevi) are
more worthy of concern.
Comparison of GP diagnosis and histopathology of lesions, and performance regarding recognition of malignant lesions
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TABLE 9 Number of cases as described by GPs on the referral form, numbers where a procedure can be shown to have been
performed and numbers of those where a histological sample was found, by trial arm
Histological sample found
GP description Total with Total  Hospital  Primary care 
GP diagnosis operated on group group
Lesions analysed
1. Unknown/non-specific description 14 14 6/7 7/7
2. Eczema/dermatitis 0 0 0/0 0/0
3. Granuloma 8 6 4/4 2/2
4. Solar elastosis 0 0 0/0 0/0
6. Sebaceous gland hyperplasia 1 1 0/0 1/1
7. Skin tag, fibroepithelial polyp, skin polyp 58 55 14/20 10/35
8. Chondrodermatitis nodularis helices 0 0 0/0 0/0
9. Viral warts 12 12 5/5 7/7
10. Scars including keloid 2 2 1/1 1/1
11. Benign tumours including neurofibroma 32 30 13/13 12/17
12. Lipoma 19 17 6/7 4/10
13. Trichilemmal cysts and epidermoids 157 143 74/90 30/53
14. Lentigo 0 0 0/0 0/0
15. Seborrhoeic keratosis, seborrhoeic wart, basal cell papilloma 148 138 57/79 43/59
16. Melanocytic naevus 159 150 66/72 62/78
17. Solar keratosis 4 4 2/2 2/2
18. Cutaneous horn 1 1 0/0 1/1
19. Bowen’s disease 1 1 1/1 0/0
20. Basal cell carcinoma 51 45 21/21 23/24
21. Keratoacanthoma 4 4 3/3 1/1
22. Squamous cell carcinoma 8 7 3/3 4/4
23. Malignant melanoma 4 4 1/1 3/3
Total 683 634 277/329 213/305
Lesions not analysed
5. Ingrowing toenail 18 17 0/9 0/8
No procedure undertaken or referred elsewhere 51 28 23
Not referred by GP 2 1 1/1 0/0
No data on referral form  2 2 0/2 0/0
Grand total 705 654 369 336Table 10 shows the numbers of cases where a
histological sample was found as described by GPs
and as classified by histological examination
(ingrowing toenails are excluded).
Agreement between GP diagnosis
and histology
An overall kappa statistic of 0.42 (95% CI 0.38 to
0.45) was obtained across the whole data set using
the 22-category classification (ingrowing toenails
excluded). This represents moderate agreement
between GP diagnosis and histological findings,
but is at the lower boundary of the moderate
category. The sensitivity analysis for missing data
improved kappa to 0.55 (95% CI 0.51 to 0.58) if
complete agreement between GP diagnosis and
histology was assumed for missing cases, but it fell
to 0.31 (95% CI 0.28 to 0.33) if complete
disagreement was assumed.
In an attempt to improve the level of agreement,
both GP referral diagnosis and histological
diagnosis were collapsed into a malignant/benign
classification and the analysis was redone. This
resulted in a kappa of 0.45 (95% CI 0.36 to 0.54).
Even at its upper 95% confidence interval,
therefore, agreement is moderate at best.
Four of the lesions (all basal cell carcinomas) were
diagnosed, correctly, in the same individual.
Similarly, many individuals had several benign
ones. The figures can be recomputed, therefore, to
reflect individuals correctly diagnosed rather than
lesions, but it becomes impossible to calculate a
kappa across all 22 categories as in some cases
individuals had a mixture of benign and
malignant lesions. Rather, they can be classified by
whether or not they were judged to have one or
more malignant lesions. The resulting kappa
statistic, calculated on 423 individuals, is 0.41
(0.32 to 0.51). Again, even at the upper level of
statistical confidence, agreement is ‘moderate’ at
best.
Test characteristics of GPs in
detecting skin malignancy
The results above can be expressed as 2 × 2 tables
and test characteristics computed. Table 11 shows
the data for individual lesions, with test
characteristics computed in the footnote, and 
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TABLE 10 Comparison of numbers (%) in each histological category as described by GPs and as classified by histological examination
(ingrowing toenails not shown)
GP diagnosis Histological diagnosis
1. Unknown/nonsense description 13 (2.6) 0
2. Eczema/dermatitis 0 2 (0.4)
3. Granuloma 6 (1.2) 12 (2.4)
4. Solar elastosis 0 9 (1.8)
6. Sebaceous gland hyperplasia 1 (0.2) 1 (0.2)
7. Skin tag, fibro-epithelial polyp, skin polyp 24 (4.7) 27 (5.3)
8. Chondrodermatitis nodularis helices 0 1 (0.2)
9. Viral warts 12 (2.4) 15 (2.9)
10. Scars including keloid 2 (0.4) 1 (0.2)
11. Benign tumours including neurofibroma 25 (4.9) 64 (12.6)
12. Lipoma 10 (2.0) 11 (2.2)
13. Cysts including epidermoids 104 (20.4) 72 (14.1)
14. Lentigo 0 7 (1.4)
15. Seborrhoeic keratosis, seborrhoeic wart, basal cell papilloma 100 (19.6) 93 (18.5)
16. Melanocytic naevus 128 (25.1) 134 (26.3)
17. Solar keratosis 4 (0.8) 4 (0.8)
18. Cutaneous horn 1 (0.2) 0
19. Bowen’s disease 1 (0.2) 3 (0.6)
20. Basal cell carcinoma 44 (8.6) 26 (5.1)
21. Keratoacanthoma 4 (0.8) 1 (0.2)
22. Squamous cell carcinoma 7 (1.4) 5 (1.0)
23. Malignant melanoma 4 (0.8) 2 (0.4)
Total 490 490
Note that figures in the second column are not a subset of figures in the first column.Table 12 is the analogous table for individuals
affected with malignancy. The results do not differ
by a great deal between the two analyses. They
indicate that, in this population, GPs failed to
recognise one-third of the skin malignancies, or
slightly more than one-third of the patients with
malignancies. Taking statistical uncertainty into
account, the upper 95% confidence interval
indicates that they miss no less than one in five.
Neither of the malignant melanomas included
here was diagnosed by the GP concerned: one was
described as a ‘dermatofibroma’ and the other
given a general description as ‘red lesion’.
Recognition of a malignancy and
completeness of excision
To investigate whether recognition of malignancy
improved completeness of excision, the 16
malignancies where surgery was undertaken by the
GP were assessed. Six out of the 11 where the
malignancy had been recognised resulted in a
complete excision (55%) compared with one of the
five (20%) where malignancy had not been
recognised. However, the association was not
statistically significant (Fisher’s exact test
p = 0.31).
Comparison of GP diagnosis and histopathology of lesions, and performance regarding recognition of malignant lesions
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TABLE 11 Benign and malignant skin lesions as judged by histology and by GP diagnosis
Histology malignant Histology benign Total
GP diagnosis malignant 24 36 60
GP diagnosis benign 12 416 428
Total 36 452 488
Sensitivity = 66.7% (52.9 to 78.00), specificity = 92.0% (89.7 to 93.9), positive predictive value = 40% (30.2 to 50.6),
negative predictive value = 97.2% (95.6 to 98.2).
TABLE 12 Individuals by whether they were judged to have a malignant skin lesion as assessed by histology and by GP diagnosis
Histology malignant Histology benign Total
Malignant diagnosis by GP 21 35 56
No malignant diagnosis by GP 12 355 367
Total 33 390 423
Sensitivity = 63.6% (49.3 to 75.9), specificity = 91.0% (88.3 to 93.1), positive predictive value = 37.5% (27.6 to 48.5),
negative predictive value = 96.7% (94.8 to 98.0).P
atients are generally happier with minor
surgery carried out in primary care rather than
hospital and, while higher quality surgical results
were achieved in the hospital arm of the trial,
their clinical importance is unclear. The perceived
advantages in terms of the convenience of 
having surgery in a local facility must be the main
positive influence on increased satisfaction with
the process of minor surgery, as it is clear that
postoperative problems are not. However, the fact
that special surgical lists were organised in the
hospital arm to avoid excessive waiting for
procedures might mean that hospital treatment
appears more attractive than it might really be,
and that the true difference may be greater than
that observed. Although confined to one
geographical area of the UK, the trial was
population based and undertaken by a large
number of practitioners in both arms, and
recruitment was from a wide variety of general
practices; therefore, the authors believe the results
to be generalisable.
Ideally, patient-level resource utilisation and costs
data would have been collected as part of the
primary study, but in the absence of these data a
cost data set was simulated using the cost data
reported in the NHS reference cost data sets for
primary and secondary care. The range of
simulated values reflects the large uncertainty
around the true mean cost of minor surgery in
both hospital and primary care. However, many of
the costs of minor surgery, from an NHS
perspective, are similar in both settings:
procedures in both arms were booked, typically, at
30-minute intervals within formal lists of three to
four patients, and if the time allocated to each
case is not fully utilised the usefulness of the
intervening time in undertaking other healthcare
activities is uncertain. Likewise, a pack with the
necessary items for minor surgery was a
requirement in both arms of the trial, and 
can be assumed to be equivalent. The cost
differences seen are likely to be primarily
attributable to differences in allocation of 
staffing and overhead costs in primary and
secondary care.
Based on patient satisfaction, and notwithstanding
small differences in surgical quality, the authors
believe it is necessary to continue providing most
minor surgery in primary care. However, there are
potentially worrying differences between primary
care and hospital doctors in the treatment of
malignancies which it may be unwise to dismiss as
being due to chance. Hospital doctors send a
higher proportion of skin lesions for pathological
examination, and upon examination more
malignant lesions are found to have been removed
adequately in hospital. The difference is unlikely
to be due to case-mix in the two study arms, 
which was very similar. In addition, using the
outcome ‘complete excision of malignancy’,
hospital minor surgery appears more effective
and, acknowledging uncertainty about 
willingness to pay, the authors believe may 
be cost-effective.
Not all malignant lesions are clinically obvious at
presentation, and some have potentially serious
adverse outcomes if missed. In this study GPs
missed one-third of malignancies, including both
of the malignant melanomas. Coupled with the
results of the trial it is clear that the major
challenge of providing minor surgery in primary
care is the potential for missed diagnosis of
serious skin malignancies.
So why is this? The 1990 contract was based on
the premise that doctors in practice were not using
skills in minor surgery that they had acquired in
medical school. However, changes in the content
of medical school curricula, coupled with
increased public expectations of certain
procedures only being carried out by ‘qualified’
doctors, mean that in most UK medical schools
minor surgery skills are no longer the province of
the medical student nor, increasingly, of the 
junior doctor. The 1990 contract gave GPs a
financial incentive to perform procedures,
therefore, for which many of them had received
little training. Perhaps it is the case that most
treatment could be carried out in primary care,
provided that GPs received further training in the
diagnosis and management of skin lesions. A
recently published trial shows that a dermatology
service operated by two GPs with special interests
gave results clinically indistinguishable from those
obtained at a hospital outpatient clinic, although
minor surgery did not form a part of the work
Health Technology Assessment 2008; Vol. 12: No. 23
25
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Chapter 7
Discussionundertaken.50 However, the general practice
service was considerably more expensive than its
hospital equivalent.51
Conclusions
Patients like the service in general practice and,
while the quality of minor surgery in primary care
is not as high as that in hospital, the difference is
not large. However, there are possible differences
between primary care and hospital doctors in the
recognition and treatment of malignant lesions
which mean that care needs to be taken in the
development of primary care-based minor 
surgery. The incidence of skin malignancies is
increasing, and a major limiting factor in
refocusing minor surgical care into the hospital
sector is limited capacity, both in terms of 
physical clinic and operating theatre space 
and in terms of medical and support staff to
undertake the procedures.52 Recently, it has been
announced that more surgical services are to be
moved into primary care, and similar issues will
apply as do here.53 Resolution of this dilemma is
not a simple matter and will extend beyond the
traditional testing of two alternative interventions.
The solution in this case may be not to avoid
primary care minor surgery, but to improve its
quality.
Recommended research
Areas for further, future study include the following:
● Further work is required to determine GPs’
management of a range of skin conditions
(including potentially life-threatening
malignancies), rather than just their recognition
of them.
● Further economic modelling work is required to
look at the potential costs of training sufficient
numbers of GPs and GPs with special interests
(GPSIs) to meet the demand for minor surgery
safely in primary care, and of the alternative of
transferring minor surgery large-scale to the
hospital sector.
● A series of models of different service
configurations should be tested to identify the
optimum service specification. Given more
capacity, one such model might include
community provision of services by specialist
dermatologists; this might prove a safe option
which is also popular with the public. Such a
service might not necessarily require treatment
of all cases by the dermatologist concerned;
diagnosis may suffice. Another might involve
testing a system in which the submission of
samples resected in primary care for histological
examination was made mandatory (or at least
encouraged).
Discussion
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F
igure 6 is a photograph of the screen with 
which the assessors marked the photographs of
the wounds. By clicking on the ‘open photo’
buttons above and to the right of each photograph,
the operator could view a full-screen version 
of the picture. There were no details of either 
who the patient was or the trial arm of the 
patient anywhere in the database file sent to the
assessors.
When marked, the program automatically returned
a file with the scores to the trial office, where it was
automatically inserted into the master database.
There was no manual transcription of scores.
Appendix 1
Wound assessment tool
FIGURE 6 Screenshot of wound assessment toolHealth Technology Assessment 2008; Vol. 12: No. 23
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Study No:
Site:
Date:
Minor Surgery Study – Patient Satisfaction Questionnaire
Thank you for agreeing to take part in our study of minor surgery. We would be interested to hear your
experiences and what happened when you went to have your minor operation, why you had it done and
what happened afterwards. Your answers will be treated as completely confidential.
Most of the questionnaire asks you to tick a box  to indicate your degree of agreement with a
statement.
For example, if you like to eat ice-cream you might strongly agree (or agree) with the following
statement:
Strongly Agree Neutral Disagree Strongly
agree disagree
I like to eat ice-cream.   
On the other hand you may not like to eat ice-cream, in which case you may strongly disagree 
(or disagree) with the following statement.
Strongly Agree Neutral Disagree Strongly
agree disagree
I like to eat ice-cream.   
The neutral box means you neither agree nor disagree with the statement.
If you would like to, please feel free to add comments on the back of this form.
Thank you.
Appendix 2
Patient Satisfaction Questionnaire I had my minor operation because:
Strongly Agree Neutral Disagree Strongly
agree disagree
1. The problem needing the operation looked    
unsightly.
2. The problem needing the operation was painful.   
3. The problem needing the operation was irritating   
me, for example by itching or rubbing on my clothes.
4. I was worried that it might be something serious.   
5. My doctor advised me to have the operation.   
6. Other reason why I had it done: ............................................................................................................
I would now like to ask you what happened
when you came for your minor operation.
Strongly Agree Neutral Disagree Strongly
agree disagree
7. I found it easy to get an appointment for the   
operation at a convenient time.
8. When I arrived to have my operation I   
had a clear idea of what was going to happen.
9. After I arrived for my operation I was able to   
wait in as much privacy as I would have liked.
10. After I arrived for my operation I was able to   
wait in as much comfort as I would have liked.
11. I felt I needed more time to discuss what to   
expect after the operation.
12. The doctor doing the operation explained   
clearly what he was going to do.
13. I had every confidence in the doctor doing   
the operation.
14. The doctor doing my operation spent enough   
time with me and didn’t hurry me.
15. I experienced more pain than I expected during   
the operation.
16. When I arrived for the operation I was not   
kept waiting very long to have it done.
17. I felt the doctor was rushed during my operation.   
18. When I had my operation I felt I didn’t have    
enough time with the doctor to discuss things
and ask all the questions I wanted to.
19. I felt I was treated with care and courtesy.   
Appendix 2
34And now I would like to ask you what happened
after your minor operation.
Strongly Agree Neutral Disagree Strongly
agree disagree
20. After my operation I was told what to do if I    
had any problems (for example bleeding or 
soreness).
21. I am satisfied with the way the wound looks now.   
22. Should the need arise I would be confident to   
undergo a similar operation in the future.
23. I think it is important that patients having an   
operation have met the doctor doing it in the 
past.
24. When I first discussed my operation with my   
doctor (GP) I was not aware that they were able 
to carry out this type of operation.
25. Had you met the doctor doing the operation in the past?
 No
 Yes – details:  ....................................................................................................................................
 Not sure
26. Did you have to take time away from paid employment in order to have your operation?
 No
 Yes – details:  ....................................................................................................................................
 Not applicable
27. Did you take any time away from paid employment in the days following your operation?
 No
 Yes – number of days: ......................................................................................................................
 Not applicable
28. Approximately how far did you have to travel from home or work to the place where you had your
operation?
................................... miles
29. If you came by car did you have trouble parking?
 No
 Yes – details:  ....................................................................................................................................
 Not applicable (e.g. travelled by public transport)
30. When you arrived for your operation about how long were you kept waiting before you had it done?
.................... hrs ................. mins
31. Altogether about how much time did you spend in travelling, waiting for your operation, having your
operation and returning home?
.................... hrs ................. mins
Health Technology Assessment 2008; Vol. 12: No. 23
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32 wound infection
33 discomfort greater than I expected
34 bleeding
35 an allergy
36 something else, please explain: ...................................................................................................
37 none of these
38. Since the operation have you been in contact with your GP? (Please tick all that apply).
 No, not regarding the operation.
 Yes – for the results of the operation.
 Yes – I was concerned about my wound. Please specify: ................................................................
Please could you tick a box to indicate whether
you agree or disagree with the following statements.
Strongly Agree Neutral Disagree Strongly
agree disagree
39. I am reassured that there is nothing serious to    
worry about.
40. I think my scar looks unsightly.   
41. In the week following the operation the wound   
was painful.
42 The wound is irritating me, for example by itching   
or rubbing on my clothes.
43. I am still worried it might have been something   
serious.
44. The appearance of the wound now is:
 much better than I expected
 better than I expected
 about what I expected
 worse than I expected
 much worse than I expected
 not applicable (for example, unable to see it)
45. If you needed another similar minor operation in the future, would you prefer to have this carried out:
 In a local hospital by a hospital doctor?
 By your GP in his surgery?
 Don’t mind, either?
 Not sure?
46. If a friend or relative asked your opinion about having a similar minor operation at the place where
you have just had yours, would you recommend it to them?
 No
 Yes
 Not sure
Thank you for your time in filling out this questionnaire.
If you would like to add any other comments about your experience that you feel are important please
feel free to do so on the back of this form.
Please return the questionnaire in the enclosed FREEPOST envelope.
Appendix 2
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Appendix 3
CONSORT statement for MiSTIC trial
Paper section  Item Description Reported 
and topic  on page(s)
Title and Abstract 1 How participants were allocated to interventions  i, iii
Introduction 2 Scientific background and explanation of rationale 1, 2
Methods
Participants  3 Eligibility criteria for participants and the settings and locations where  6
the data were collected
Interventions 4 Precise details of the interventions intended for each group and how 
and when they were actually administered 6
Objectives 5 Specific objectives and hypotheses 3
Outcomes 6 Clearly defined primary and secondary outcome measures and, when 
applicable, any methods used to enhance the quality of measurements 6–9
Sample size 7 How sample size was determined and, when applicable, explanation 
of any interim analyses and stopping rules 6
Randomisation –  8 Method used to generate the random allocation sequence, including  11
sequence generation details of any restriction
Randomisation – 9 Method used to implement the random allocation sequence, clarifying  11
allocation concealment whether the sequence was concealed until interventions were assigned
Randomisation – 10 Who generated the allocation sequence, who enrolled participants, and  11
implementation who assigned participants to their groups
Blinding (masking)  11 Whether or not participants, those administering the interventions and  8, 11–12
those assessing the outcomes were blinded to group assignment
Statistical methods  12 Statistical methods used to compare groups for primary outcome(s);  8–9
methods for additional analyses, such as subgroup analyses and 
adjusted analyses
Results 13 Flow of participants through each stage (a diagram is strongly  11, 13
Participant flow recommended). Specifically, for each group report the numbers of 
participants randomly assigned, receiving intended treatment, 
completing the study protocol and analysed for the primary outcome. 
Describe protocol deviations from study as planned, together with 
reasons
Recruitment 14 Dates defining the periods of recruitment and follow-up 6
Baseline data  15 Baseline demographic and clinical characteristics of each group 13–16
Numbers analysed 16 Number of participants (denominator) in each group included in each  9, 13–16
analysis and whether the analysis was by ‘intention-to-treat’. State 
the results in absolute numbers
Outcomes and estimation  17 For each primary and secondary outcome, a summary of results for  13–24
each group, and the estimated effect size and its precision
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed,  NA
including subgroup analyses and adjusted analyses, indicating those 
prespecified and those exploratory
Adverse events  19 All important adverse events or side-effects in each intervention group NA
Discussion
Interpretation  20 Interpretation of the results, taking into account study hypotheses,  25, 26
sources of potential bias or imprecision and the dangers associated 
with multiplicity of analyses and outcomes
Generalisability  21 Generalisability (external validity) of the trial findings 25
Overall evidence  22 General interpretation of the results in the context of current evidence 25, 26Appendix 3
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Patients eligible for recruitment
n = 2500 
284 in GP arm 284 in hospital arm
568 randomised
Dropped out or
lost to follow-up
n = 23
Dropped out or
lost to follow-up
n = 26
Completed treatment
n = 261
Completed treatment
n = 258
Photographed
scar
n = 273/312
a
Photographed
scar
n = 316/340
a
Completed
questionnaires
n = 228
Completed
questionnaires
n = 239
Pathological sample
n = 213/293
Pathological sample
n = 278/325
FIGURE 7 Flow diagram for MiSTIC trial. (aIncludes ingrowing toenails). Health Technology Assessment 2008; Vol. 12: No. 23
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